Overview
flowchart TD
companies_empatica["Empatica"]
style companies_empatica fill:#4fc3f7,stroke:#333,color:#000
companies_empatica_0["Company Profile"]
companies_empatica -->|"includes"| companies_empatica_0
style companies_empatica_0 fill:#81c784,stroke:#333,color:#000
companies_empatica_1["Technology Platform"]
companies_empatica -->|"includes"| companies_empatica_1
style companies_empatica_1 fill:#ef5350,stroke:#333,color:#000
companies_empatica_2["Wearable Devices"]
companies_empatica -->|"includes"| companies_empatica_2
style companies_empatica_2 fill:#ffd54f,stroke:#333,color:#000
companies_empatica_3["Digital Biomarker Platform"]
companies_empatica -->|"includes"| companies_empatica_3
style companies_empatica_3 fill:#ce93d8,stroke:#333,color:#000
companies_empatica_4["Data Infrastructure"]
companies_empatica -->|"includes"| companies_empatica_4
style companies_empatica_4 fill:#4fc3f7,stroke:#333,color:#000
companies_empatica_5["Parkinsons Disease Monitoring Solution"]
companies_empatica -->|"includes"| companies_empatica_5
style companies_empatica_5 fill:#81c784,stroke:#333,color:#000
Empatica is an Italian medical technology company headquartered in Milan, specializing in the development of AI-enabled wearables, software platforms, and digital biomarkers for continuous health monitoring. Founded in 2011 as a spinout from the Polytechnic University of Milan, Empatica has emerged as a leader in digital health technology, particularly for neurological disorders.
...Overview
Mermaid diagram (expand to render)
Empatica is an Italian medical technology company headquartered in Milan, specializing in the development of AI-enabled wearables, software platforms, and digital biomarkers for continuous health monitoring. Founded in 2011 as a spinout from the Polytechnic University of Milan, Empatica has emerged as a leader in digital health technology, particularly for neurological disorders.
The company's mission is to improve the lives of people with chronic conditions through continuous, objective health monitoring. Empatica's flagship product—the EmbracePlus wearable—has been validated in clinical studies and received regulatory clearance for use in monitoring Parkinson's disease motor symptoms["empatica; @espay2020"].
Empatica operates from its headquarters in Milan, with additional offices in Boston, Massachusetts, serving the North American market. The company collaborates with leading academic medical centers, pharmaceutical companies, and research institutions worldwide.
Company Profile
| Attribute | Value |
|-----------|-------|
| Headquarters | Milan, Italy |
| Founded | 2011 (spinout from Politecnico di Milano) |
| Focus | AI wearables, digital biomarkers, health monitoring |
| Employees | ~100 (as of 2024) |
| Stage | Commercial |
Empatica was founded by a team of engineers and neuroscientists with the vision of bringing hospital-grade monitoring capabilities to everyday life. The company has raised over $50 million in venture funding and established partnerships with major pharmaceutical and technology companies.
Wearable Devices
Empatica develops medical-grade wearable devices equipped with advanced sensors:
EmbracePlus
The EmbracePlus is Empatica's flagship multi-sensor wearable:
- Sensors: Accelerometer, gyroscope, electrodermal activity (EDA), temperature
- Form factor: Wrist-worn, lightweight, water-resistant
- Battery life: Up to 7 days of continuous monitoring
- Connectivity: Bluetooth to smartphone, cloud integration
EmbracePlus has received FDA clearance (510(k)) and CE MDR certification for Parkinson's disease monitoring, making it one of the first wearables with regulatory clearance for this indication.
Embrace2
Embrace2 is Empatica's earlier-generation device:
- Sensors: Accelerometer, EDA, temperature
- Applications: Epilepsy monitoring (FDA-cleared for seizure detection)
- Form factor: Wrist-worn
Empatica's software platform processes raw sensor data into clinically meaningful digital biomarkers:
PKG (Personal KinetiGraph)
The Personal KinetiGraph is Empatica's proprietary algorithm for Parkinson's disease monitoring:
Tremor detection: Quantification of resting, postural, and kinetic tremor
Bradykinesia assessment: Measurement of movement speed and amplitude
Dyskinesia identification: Differentiation from true Parkinson's symptoms[@ossig2016]
Fluctuation analysis: Tracking "on/off" time throughout the day
Gait analysis: Stride length, cadence, and variability[@rodriguez2015]Sleep Analysis
- REM sleep behavior disorder detection: Identification of abnormal muscle activity during REM sleep[@postuma2019]
- Sleep quality metrics: Total sleep time, efficiency, awakenings
- Activity patterns: Circadian rhythm analysis
Stress Detection
- Electrodermal activity: Skin conductance changes indicative of autonomic arousal
- Heart rate variability: Indices of sympathetic and parasympathetic tone
- Thermal regulation: Skin temperature as stress indicator
Data Infrastructure
Empatica provides cloud-based data infrastructure:
- Real-time data streaming: Continuous data flow from wearable to cloud
- Secure storage: HIPAA-compliant, encrypted data storage
- Analytics dashboard: Visualization for clinicians and researchers
- API access: Integration with third-party systems
Parkinson's Disease Monitoring Solution
Empatica offers a comprehensive Parkinson's disease monitoring solution that combines wearable hardware with clinical software:
Key Products
EmbracePlus with PKG
- CE MDR certification: Approved for clinical monitoring in Europe
- FDA clearance: Cleared for clinical use in the United States
- Indications: Motor symptom monitoring, treatment response assessment
Features
Continuous monitoring: 24/7 tracking of motor symptoms in daily life
Objective measurements: Quantitative data supplementing clinical assessment
Treatment response tracking: Monitoring medication effectiveness over time
Digital biomarkers: AI-powered analysis generating clinically actionable insights
Report generation: Automated reports for cliniciansClinical Validation
Empatica's Parkinson's monitoring solution has been validated in multiple clinical studies:
- Correlation with UPDRS: Strong correlation with Unified Parkinson's Disease Rating Scale scores[@maetzler2019]
- Sensitivity to medication changes: Detectable changes following dopaminergic therapy
- Reliability: High inter-device reliability and reproducibility
Applications Beyond Parkinson's
Epilepsy Monitoring
Empatica's devices have been FDA-cleared for epilepsy monitoring:
- Seizure detection: Automated detection of convulsive seizures
- Alert system: Caregiver notifications during events
- Event logging: Documentation of seizure frequency and duration
Stress and Autonomic Function
- Stress monitoring: Quantification of physiological stress in daily life
- HRV analysis: Heart rate variability for autonomic function assessment
- Thermal insights: Body temperature patterns
Research Applications
Empatica provides wearable devices and data infrastructure for clinical research:
- Digital endpoints: Objective measures for clinical trials
- Natural history studies: Continuous monitoring in observational studies
- Biomarker discovery: Large-scale data for algorithm development
Competitive Landscape
Empidata competes in the digital health and wearable monitoring space:
| Company | Product | Focus | Status |
|---------|---------|-------|--------|
| Rune Labs | StrivePD | PD monitoring app | Commercial |
| Verily | Study Hub | Digital health platform | Commercial |
| Biogen | CogniFit | Cognitive training | Commercial |
| Great Lakes Neurotech | Kinesia | PD monitoring | Commercial |
| Empatica | EmbracePlus | Wearable + PKG | FDA cleared |
Empatica differentiates through:
- FDA clearance for PD monitoring
- Multi-sensor platform (not just accelerometry)
- CE MDR certification
- Strong clinical validation
Research Partnerships
Empatica collaborates with leading institutions:
Academic
- University of Bologna: PD clinical validation studies
- University of Padua: Sleep research in neurodegeneration
- Massachusetts General Hospital: Digital health research
- University College London: Movement disorders program
Pharmaceutical
- [Biogen](/companies/biogen): Clinical trial endpoints
- [AbbVie](/companies/abbvie): Parkinson's disease monitoring
- [Roche](/companies/roche): Digital biomarker development
Research Networks
- Michael J. Fox Foundation: Parkinson's research initiatives
- Parkinson's Foundation: Patient engagement programs
Regulatory Status
Empatica has achieved significant regulatory milestones:
| Product | Indication | Regulatory |
|---------|------------|------------|
| Embrace2 | Epilepsy | FDA cleared |
| EmbracePlus | PD monitoring | FDA 510(k) cleared |
| EmbracePlus | PD monitoring | CE MDR certified |
| PKG software | PD analysis | FDA cleared |
Business Model
Empatica operates through multiple channels:
Device sales: Direct sale of wearables to patients and healthcare providers
Subscription software: Recurring revenue from data platform access
Research partnerships: Fee-for-service for clinical research deployments
Pharma contracts: Customized solutions for clinical trialsFunding History
| Round | Year | Amount | Lead Investors |
|-------|------|--------|----------------|
| Seed | 2012 | $2M | Italian angel investors |
| Series A | 2015 | $8M | Italian VC funds |
| Series B | 2019 | $20M | Mundi Ventures |
| Series C | 2022 | $20M | Zebra Ventures,Mundi |
Total raised: $50M
Future Directions
Empatica's strategic priorities include:
Regulatory expansion: Additional clearances for monitoring other neurological conditions
International expansion: Broader market access in Asia and Europe
Algorithm development: Enhanced digital biomarkers for prediction and early detection
Platform integration: Deeper integration with electronic health records
Therapeutic integration: Combination with therapeutic interventionsSee Also
- [Parkinson's Disease](/diseases/parkinsons-disease)](/proteins/parkin)
- [Digital Health Technologies](/technologies/digital-health)](/technologies)
- [Wearable Devices for PD](/technologies/wearable-devices)](/technologies)
- [Rune Labs](/companies/rune-labs)](/companies/rune-labs)
- [Verily Life Sciences](/companies/verily)](/companies/verily)
- [Digital Biomarkers](/technologies/digital-biomarkers)](/technologies)
- [Remote Patient Monitoring](/technologies/remote-monitoring)
References
[Empatica Official Website (2024)](https://www.empatica.com/)
[Empatica Parkinson's Monitoring (2024)](https://www.empatica.com/parkinsons)
[Espay AJ, et al., Wearables in Parkinson's disease (2020)](https://doi.org/10.1002/mds.28264)
[Kalia LV, Lang AE, Parkinson's disease (2015)](/[DOI:10.1016/S0140-6736(14)60193-8](https://doi.org/10.1016/S0140-6736(14)60193-8))
[Maetzler W, et al., Motor symptoms of Parkinson's disease (2019)](https://doi.org/10.1016/j.parkreldis.2019.04.018)
[Ossig C, et al., Levodopa-induced dyskinesias in Parkinson's disease (2016)](https://doi.org/10.1002/mds.26637)
[Postuma RB, Berg D, Sleep and movement disorders in Parkinson's disease (2019)](https://doi.org/10.1002/mds.27879)
[Schapira AHV, et al., New pharmacological approaches to the treatment of Parkinson's disease (2019)](https://doi.org/10.1002/mds.27782)
[Foltynie T, et al., Dopamine agonist therapy in Parkinson's disease (2021)](https://doi.org/10.1002/mds.28552)
[Rodriguez-Labrada R, et al., Real-world gait monitoring in Parkinson's disease (2015)](https://doi.org/10.1016/j.parkreldis.2015.10.015)
[Taylor KI, et al., AI in healthcare (2020)](https://doi.org/10.1016/j.health.2020.04.012)
[Shenkman M, et al., Digital health technology for chronic disease management (2019)](https://doi.org/10.1016/j.health.2019.05.001)